$MGNC
Mag Magna Corp

2024 Q1 Form 10-Q Financial Statement

#000194986424000003 Filed on March 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q2
Revenue $4.200K $1.400K
YoY Change
Cost Of Revenue $1.400K
YoY Change
Gross Profit $4.200K $1.400K
YoY Change
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.284K $7.071K
YoY Change -16.18% 84.28%
Operating Profit $2.084K $5.671K
YoY Change -72.2% -247.8%
Interest Expense $6.00 $5.00
YoY Change 100.0%
% of Operating Profit 0.29% 0.09%
Other Income/Expense, Net $6.00 $5.00
YoY Change 100.0%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.078K -$5.666K
YoY Change -72.27% 47.78%
Net Earnings / Revenue -49.48% -404.71%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 5.657M shares 4.500M shares
Diluted Shares Outstanding 5.290M shares 4.500M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $11.54K $4.484K $4.513K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $9.000K
Receivables
Other Receivables
Total Short-Term Assets $11.54K $4.00 $4.513K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $17.81K $15.64K $8.206K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $26.31K $20.12K $17.21K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $11.54K $4.00 $4.513K
Total Long-Term Assets $26.31K $20.12K $17.21K
Total Assets $37.84K $20.12K $21.72K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.68K $46.63K $35.14K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $46.68K $46.63K $35.14K
Total Long-Term Liabilities
Total Liabilities $46.68K $46.63K $35.14K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $15.16K -$13.09K $17.92K
YoY Change
Common Stock $24.25K $4.500K $4.500K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.834K -$26.50K -$13.42K
YoY Change
Total Liabilities & Shareholders Equity $37.84K $20.12K $21.72K
YoY Change

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.078K -$5.666K
YoY Change -72.27% 47.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$9.145K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.600K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.75K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $19.80K
YoY Change
NET CHANGE
Cash From Operating Activities -$9.145K
Cash From Investing Activities -$3.600K
Cash From Financing Activities $19.80K
Net Change In Cash $7.051K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$9.145K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001949864
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
usd
CY2023Q1 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-01-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-268561
dei Entity Registrant Name
EntityRegistrantName
MAG MAGNA CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1626237
dei Entity Address Address Line1
EntityAddressAddressLine1
325 W Washington St Ste 2877
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92103
dei City Area Code
CityAreaCode
620
dei Local Phone Number
LocalPhoneNumber
4692043
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5656647 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11535 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4513 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
11535 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
4513 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17806 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8206 usd
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
8500 usd
CY2023Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
9000 usd
CY2024Q1 us-gaap Other Assets
OtherAssets
26306 usd
CY2023Q2 us-gaap Other Assets
OtherAssets
17206 usd
CY2024Q1 us-gaap Assets
Assets
37841 usd
CY2023Q2 us-gaap Assets
Assets
21719 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
46675 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
35136 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
46675 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
35136 usd
CY2024Q1 us-gaap Liabilities
Liabilities
46675 usd
CY2023Q2 us-gaap Liabilities
Liabilities
35136 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5289847 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5289847 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4500000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4500000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5290 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4500 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18956 usd
CY2024Q1 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
17917 usd
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
-1 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15163 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
17918 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-8834 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-13417 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37841 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21719 usd
CY2024Q1 us-gaap Revenues
Revenues
4200 usd
us-gaap Revenues
Revenues
5600 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
4200 usd
us-gaap Gross Profit
GrossProfit
5600 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6284 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20780 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7497 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14396 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
6284 usd
us-gaap Operating Expenses
OperatingExpenses
20780 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7497 usd
us-gaap Operating Expenses
OperatingExpenses
14396 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
2084 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
15180 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7497 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14396 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
6 usd
us-gaap Interest Expense
InterestExpense
17 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
3 usd
us-gaap Interest Expense
InterestExpense
8 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2078 usd
us-gaap Net Income Loss
NetIncomeLoss
-15163 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7494 usd
us-gaap Net Income Loss
NetIncomeLoss
-14388 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5289847 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5289847 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4500000 shares
CY2022Q2 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4501 usd
us-gaap Net Income Loss
NetIncomeLoss
-14388 usd
CY2023Q2 us-gaap Shares Issued
SharesIssued
4500000 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-13417 usd
us-gaap Net Income Loss
NetIncomeLoss
-15163 usd
CY2022Q4 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2393 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7494 usd
CY2023Q1 us-gaap Shares Outstanding
SharesOutstanding
4500000 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9887 usd
CY2023Q4 us-gaap Shares Issued
SharesIssued
4500000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-26502 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2078 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
789847 shares
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19746 usd
CY2024Q1 us-gaap Shares Issued
SharesIssued
5289847 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-8834 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2078 usd
us-gaap Profit Loss
ProfitLoss
-15163 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1433 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3001 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8500 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-500 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9145 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11662 usd
CY2024Q1 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
3600 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
12600 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3600 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12600 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
11538 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19746 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19746 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19796 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31284 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7051 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7022 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4484 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4513 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11535 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11535 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_z2zuNuPRBaUa" style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0 9pt; text-indent: 0.5in"><i><span id="xdx_860_zUI1XpHHfW77">Use of Estimates</span></i></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 0.5in"> </p>
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
46675 usd
CY2024Q1 us-gaap Stockholders Equity Period Increase Decrease
StockholdersEquityPeriodIncreaseDecrease
789847 usd
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
5289847 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
270400 shares
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
135200 shares

Files In Submission

Name View Source Status
0001949864-24-000003-index-headers.html Edgar Link pending
0001949864-24-000003-index.html Edgar Link pending
0001949864-24-000003.txt Edgar Link pending
0001949864-24-000003-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
magna10q31jan2024.htm Edgar Link pending
MetaLinks.json Edgar Link pending
none-20240131.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
none-20240131_cal.xml Edgar Link unprocessable
none-20240131_def.xml Edgar Link unprocessable
none-20240131_lab.xml Edgar Link unprocessable
none-20240131_pre.xml Edgar Link unprocessable
magna10q31jan2024_htm.xml Edgar Link completed